Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.76 |
| ▸ | GLP1R | P43220 | 8/20 | 0.70 |
| ▸ | ECE1 | P42892 | 1/20 | 0.69 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.69 |
| ▸ | CCKBR | P32239 | 1/20 | 0.68 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.67 |
| ▸ | CALCA | P06881 | 2/20 | 0.65 |
| ▸ | NPY2R | P49146 | 2/20 | 0.64 |
| ▸ | GHSR | Q92847 | 2/20 | 0.64 |
| ▸ | GCGR | P47871 | 1/20 | 0.64 |
| ▸ | GIPR | P48546 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29736864 | 0.97 | NR3C1 (0.72) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL29736869 | 0.94 | NR3C1 (0.72) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL31140800 | 0.92 | GLP1R (0.70) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL30008855 | 0.91 | NR3C1 (0.70) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL29983249 | 0.91 | NR3C1 (0.69) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL29358003 | 0.89 | NR3C1 (0.66) | NR3C1GLP1RECE1MUS81IL23R | |
| SCHEMBL30008333 | 0.89 | PTH1R (0.66) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL30683162 | 0.88 | GLP1R (0.81) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL29360422 | 0.88 | GLP1R (0.88) | NR3C1GLP1RECE1MUS81CCKBR | |
| SCHEMBL29366649 | 0.88 | GLP1R (0.88) | NR3C1GLP1RECE1MUS81CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-14 | — | — | US | claimed |
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | INCYTE CORP (US) | 2026-05-07 | — | — | US | claimed |
| EP-4736856-A2 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735420-A1 | ARYL INDOL-3-YL KETONE AND ARYL INDAZOL-3-YL KETONE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4727548-A1 | METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12600722-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | claimed |
| US-12600723-B2 | Tetracyclic compounds as DGK inhibitors | INCYTE CORPORATION (US) | 2026-04-14 | — | — | US | claimed |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | INCYTE CORPORATION (US) | 2026-04-09 | — | — | US | claimed |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | INCYTE CORP (US) | 2026-04-09 | — | — | US | claimed |
| US-20260070914-A1 | SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | claimed |
| WO-2022204112-A1 | IMIDAZOLE AND TRIAZOLE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2022-09-29 | — | — | WO | claimed |
| US-11447494-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-20 | — | — | US | claimed |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-09-13 | — | — | US | claimed |
| EP-4041731-A1 | BICYCLIC AMINES AS CDK2 INHIBITORS | Incyte Corporation (US) | 2022-08-17 | — | — | EP | claimed |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-07-26 | — | — | US | claimed |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-07-07 | — | — | US | claimed |
| WO-2022140231-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION (US) | 2022-06-30 | — | — | WO | claimed |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORPORATION | 2022-06-02 | — | — | US | claimed |
| WO-2022072783-A1 | BICYCLIC DIONE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2022-04-07 | — | — | WO | claimed |
| WO-2022047093-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2022-03-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070914-A1 | SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS | CCNA1, CCNO, CDK1 | NR3C1 12/4885GLP1R 3156/4885ECE1 1973/4885 |
| US-20220213108-A1 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, VHL | NR3C1 4012/4885GLP1R 4304/4885ECE1 2193/4885 |
| US-20260132122-A1 | 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS | CCNA1, CDK4, CCNO | NR3C1 44/4885GLP1R 4328/4885ECE1 3258/4885 |
| US-20260098041-A1 | FUSED BICYCLIC PYRIMIDONES AS WRN INHIBITORS | WRN, POLR1A, REV1 | NR3C1 7/4885GLP1R 2358/4885ECE1 1970/4885 |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3CA, PIK3CG | NR3C1 2251/4885GLP1R 1461/4885ECE1 3014/4885 |
| US-20260125391-A1 | PYRIMIDINE INDOLES AS CDK4 INHIBITORS | CDK4, CCNA1, CCNO | NR3C1 72/4885GLP1R 3823/4885ECE1 3167/4885 |
| US-11447494-B2 | Tricyclic amine compounds as CDK2 inhibitors | CDK2, CDK1, CCNI | NR3C1 2388/4885GLP1R 4702/4885ECE1 1194/4885 |
| US-20220169649-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | NR3C1 4463/4885GLP1R 4000/4885ECE1 1831/4885 |
| US-11440914-B2 | Tricyclic amine compounds as CDK2 inhibitors | CDK2, CDK1, CCNI | NR3C1 2428/4885GLP1R 4733/4885ECE1 1510/4885 |
| US-12600723-B2 | Tetracyclic compounds as DGK inhibitors | DGKB, DGKA, NR2C2 | NR3C1 99/4885GLP1R 3648/4885ECE1 4098/4885 |
| US-20260098044-A1 | TRICYCLIC HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2 AND/OR JAK1 | JAK1, TYK2, JAK2 | NR3C1 25/4885GLP1R 1425/4885ECE1 2413/4885 |
| US-12600722-B2 | Tetracyclic compounds as DGK inhibitors | DGKB, DGKA, DGKK | NR3C1 193/4885GLP1R 3940/4885ECE1 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.